The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 23, 2023

Filed:

Aug. 13, 2021
Applicant:

Elixir Medical Corporation, Milpitas, CA (US);

Inventors:

Motasim Sirhan, Los Altos, CA (US);

Xiaoxia Zheng, Fremont, CA (US);

Vinayak D. Bhat, Cupertino, CA (US);

John Yan, Los Gatos, CA (US);

Assignee:

Elixir Medical Corporation, Milpitas, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); A61F 2/82 (2013.01); A61L 27/50 (2006.01); A61L 27/54 (2006.01); A61L 31/16 (2006.01); A61L 33/00 (2006.01); A61L 27/20 (2006.01); A61L 27/34 (2006.01); A61L 31/04 (2006.01); A61L 31/10 (2006.01); A61L 33/08 (2006.01); A61K 31/4545 (2006.01); A61L 27/58 (2006.01); A61F 2/844 (2013.01); A61K 31/727 (2006.01); A61F 2/848 (2013.01); A61K 31/4709 (2006.01);
U.S. Cl.
CPC ...
A61F 2/844 (2013.01); A61F 2/82 (2013.01); A61F 2/848 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 31/5377 (2013.01); A61K 31/727 (2013.01); A61L 27/20 (2013.01); A61L 27/34 (2013.01); A61L 27/507 (2013.01); A61L 27/54 (2013.01); A61L 31/04 (2013.01); A61L 31/042 (2013.01); A61L 31/10 (2013.01); A61L 31/16 (2013.01); A61L 33/0011 (2013.01); A61L 33/08 (2013.01); A61F 2210/0004 (2013.01); A61F 2220/0008 (2013.01); A61F 2250/0035 (2013.01); A61F 2250/0068 (2013.01); A61L 27/58 (2013.01);
Abstract

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.


Find Patent Forward Citations

Loading…